Lucius LuciTeno TAF Tenofovir 25mg

Product Information

• Product name: LuciTeno TAF Tenofovir 25mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Tenofovir
• Current strength: 25mg
• SKU: LU-ITEM-116
• Site category: hepatitis B, other cancer

Product Summary

LuciTeno TAF Tenofovir 25mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Tenofovir is the active ingredient used for this product page. Public prescribing information for Tenofovir was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Tenofovir is a fixed dose combination of antiretroviral drugs bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF) .

Reference Indications

Tenofovir is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg: who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir.

Reference Dosage and Administration

Recommended dosage in adults and pediatric patients weighing at least 25 kg: One tablet containing 50 mg BIC, 200 mg FTC, and 25 mg TAF taken once daily with or without food.

With this 25mg product, that corresponds to 2 x 25mg tablets when that reference dose is clinically appropriate.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine (FTC) and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of Tenofovir. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue Tenofovir. If appropriate, anti-hepatitis B therapy may be warranted . WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B See for complete boxed warning.

Common Adverse Reactions and Monitoring

Immune Reconstitution Syndrome . New Onset or Worsening Renal Impairment . Lactic Acidosis/Severe Hepatomegaly with Steatosis . Clinical Trials in Adults with No Antiretroviral Treatment History The primary safety assessment of Tenofovir was based on data from two randomized, double-blind, active-controlled trials, Trial 1489 and Trial 1490, that enrolled 1274 HIV-1 infected adult subjects with no antiretroviral treatment history through Week 144. After Week 144, subjects received open-label Tenofovir in an optional extension phase for an additional 96 weeks (end of study).

Drug Interactions and Special Populations

Because Tenofovir is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. ( 4 , 5.2 , 7 , 12.3 ) 7.1 Other Antiretroviral Medications Because Tenofovir is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended . Coadministration of Tenofovir with drugs that are substrates of OCT2 and MATE1 (e.g., dofetilide) may increase their plasma concentrations (see Table 3 ). A drug that is a strong inducer of CYP3A and also an inducer of UGT1A1 can substantially decrease the plasma concentrations of BIC which may lead to loss of therapeutic effect of Tenofovir and development of resistance .

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: Biktarvy public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.